IKT$1.557.19%-0.12
After Hours: 1.53-0.02 -1.29%
Inhibikase Therapeutics Inc (IKT)
Date: 2026-10-30 16:00O: 1.67H: 1.67L: 1.52C: 1.55Vol: 438.0k
Inhibikase Therapeutics Inc stock is traded at $1.55, with a volume of 437,986. It is down -7.19% in the last 24 hours and down -24.57% over the past month. Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Previous Close:
$1.67
Open:
$1.67
24h Volume:
437,986
Relative Volume:
0.66
Market Cap:
$216.28M
Revenue:
$79,600
Net Income/Loss:
-$48.26M
P/E Ratio:
-
EPS:
-$0.4922
Net Cash Flow:
-$28.24M
1W Performance:
-2.52%
1M Performance:
-24.57%
6M Performance:
-17.99%
1Y Performance:
+6.16%
1-Day Range:
$1.52$1.67
1-Week Range:
$1.50$1.70
52-Week Range:
$1.33$2.61
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(302) 295-3800Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON, USACompare IKT vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT Inhibikase Therapeutics Inc | $1.55 | $216.28M | $79,600 | -$48.26M | -$28.24M | -$0.4922 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inhibikase Therapeutics Inc Stock (IKT) Insider Trading
- Sands Capital Life Sciences PuNov 21 '2510% Owner
- Transaction
- Buy
- Cost
- $1.45
- #Shares
- 2,068,965
- Value ($)
- 2,999,999
- #Shares Total
- 13,018,965
